Nautilus Biotechnology debuts as a publicly traded company,
- Business combination transaction with Arya Sciences Acquisition Corp III, a special purpose acquisition company sponsored by Perceptive Advisors, closed on June 9, 2021
- Renowned public company Nautilus Biotechnology, Inc.
- Common shares begin trading under the symbol “NAUT” on the Nasdaq Global Select Market on June 10, 2021
- Gross proceeds from this transaction to Nautilus totaled approximately $ 345 million, combining approximately $ 145 million of funds held in Arya III’s trust account and concurrent PIPE funding of $ 200 million.
SEATTLE and NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) – Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform to quantify the proteome, today announced the completion of its merger with Arya Sciences Acquisition Corp III (Nasdaq: ARYA; or “Arya III”), a Special Purpose Acquisition Company (SPAC) sponsored by Perceptive Advisors. The combined company, Nautilus Biotechnology, Inc. (“Nautilus”), will begin trading its common shares under the symbol “NAUT” on the Nasdaq Global Select Market on June 10, 2021.
The business combination was approved by the shareholders of Arya III on June 8, 2021. The transaction had been previously approved by the shareholders of Nautilus. The gross proceeds of this transaction were approximately $ 345 million, including approximately $ 145 million of funds held in the Arya III trust account and the concurrent private investment in common shares in the public equity financing. (PIPE) of $ 200 million led by Perceptive Advisors, a subsidiary of Arya III sponsor, as well as RA Capital Management, Ally Bridge Group, Bain Capital Life Sciences, Franklin Templeton Investments, OrbiMed, Alyeska Investment Group, LP, Casdin Capital and the existing shareholders of Nautilus Biotechnology, including Andreessen Horowitz, Madrona Venture Group and Vulcan Capital. Nautilus’ management team, led by its founders, CEO Sujal Patel and Chief Scientist Parag Mallick, will continue to lead the combined company.
“At Nautilus, we have redesigned the way to comprehensively analyze and quantify the proteome. In doing so, we seek to create a new gold standard in the field of proteomics that will have positive effects on human health, ”said Sujal Patel, CEO of Nautilus. “We believe our technology will change the scale of what is possible in proteomics in an effort to enable significant advances in drug development and help revolutionize the way biomedical research is conducted.”
Nautilus is developing a protein analysis platform with the potential to identify more than 95% of the proteome. Integrated with breakthrough innovations in computer science, engineering and biochemistry, the Nautilus proteomic analysis platform is designed to take advantage of a large-scale nanofabricated single-molecule protein matrix, multi-cycle imaging and of a machine learning analysis to measure the proteome with extreme sensitivity and scale.
“By combining a team of seasoned leaders in technology and life sciences with an unprecedented and truly innovative approach to proteomics, we believe Nautilus is poised to not only elevate, but radically reinvent our understanding. of the proteome, ”said Adam Stone, Chief Investment Officer of Perceptive Advisors and former CEO of Arya III. “We are proud to partner with Nautilus in the hope of leading the proteomics revolution towards better health and medical interventions. “
“We are committed to taking a bold scientific step towards democratizing access to the proteome and transforming the way human diseases are fundamentally understood and treated,” said Parag Mallick, chief scientist at Nautilus. “By providing the simplicity, speed, sensitivity and ubiquity that will truly unlock the potential of the proteome, we believe we can open the door to endless opportunities in scientific discovery, from the discovery of new therapies and diagnostics to revolution in basic scientific research. “
Note on the transaction summary
The description of the business combination contained herein is only a high level summary and is qualified in its entirety by reference to the underlying documents filed with the United States Securities and Exchange Commission (“SEC”). United. A more detailed description of the terms of the transaction has been provided in a registration statement on Form S-4 filed with the SEC BY Arya III, which the SEC has declared effective and which contains a final power of attorney / final prospectus relating to the transaction.
Morgan Stanley acted as principal financial advisor to Nautilus Biotechnology. Cowen also acted as financial advisor to Nautilus Biotechnology. Jefferies LLC and Goldman Sachs & Co. LLC acted as financial advisers to Arya III as well as private placement agents. Wilson Sonsini Goodrich & Rosati, PC acted as legal counsel to Nautilus Biotechnology. Kirkland & Ellis LLP acted as legal counsel to Arya III.
About Nautilus Biotechnology, Inc.
Based in Seattle, WA, Nautilus is a developing life science company creating a technology platform to quantify and unlock the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advances in the field of human health and medicine. To learn more about Nautilus, visit nautilus.bio
Special Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws. You can identify forward-looking statements by words such as “may”, “will”, “could”, “could”, “could”, “should”, “expect”, “intend”, ” plan “,” anticipate, “” believe “,” estimate “,” predict “,” project “,” potential “,” on point “,” continue “,” in progress “or the negative of these terms or other comparable terminology, but not all forward-looking statements will contain these words. Forward-looking statements contained in this press release include, without limitation, statements regarding the functionality and potential performance of Nautilus’ product platform, its potential impact on pharmaceutical development and drug discovery, and the market opportunities available to Nautilus in general. These statements are based on numerous assumptions regarding the development of Nautilus’ products and target markets and involve substantial risks, uncertainties and other factors which may cause actual results, levels of activity, performance to occur. or the achievements are materially different from the information expressed or implied by these forward-looking statements. We cannot assure you that the forward-looking statements contained in this press release or the assumptions on which they are based will prove to be correct. Risks and uncertainties that could materially affect the accuracy of Nautilus’ assumptions and its ability to achieve the forward-looking statements set out in this press release include (but are not limited to) the following: The Nautilus product platform does not is not yet commercially available and remains subject to significant scientific and technical development, which is inherently difficult and difficult to predict, especially with regard to very new and complex products such as those developed by Nautilus. Even if our development efforts are successful, our product platform will require substantial validation of its functionality and usefulness in life science research. During the scientific and technical development of Nautilus and the validation and commercialization of associated products, we may experience significant delays due to unforeseen events. We cannot provide any guarantee or assurance with respect to the outcome of our development and commercialization initiatives or with regard to their associated timelines. For a more detailed description of the additional risks and uncertainties that Nautilus faces and its development efforts, investors should refer to the registration statement on Form S-4 and related documents filed by Arya III with the SEC. The forward-looking statements contained in this press release are as of the date of this press release. Unless otherwise provided by applicable law, Nautilus and Arya III disclaim any obligation to update forward-looking statements. You should therefore not rely on these forward-looking statements as representing our opinions as of a date subsequent to the date of this press release.
Thermal for Nautilus Biotechnology
investor [email protected]